Generation of Antibody Drug Conjugate (ADC) technologies for site specific conjugation to toxins

Lead Research Organisation: King's College London
Department Name: Genetics and Molecular Medicine

Abstract

Antibody-Drug Conjugates (ADCs) are a targeted treatment technology for delivery of toxins
directly to cancer cells and a fast-growing class of oncology therapeutics, with eight ADCs
approved for clinical use. Most clinically-available ADCs are produced through either a
chemical reaction of lysine e-amino groups which produces heterogeneous products, or
conjugation through cysteine sulfhydryl groups activated by reducing the interchain disulfide
bonds, which may compromise antibody stability. We will introduce site-specific cysteine
mutations on antibodies for site-specific conjugation with toxic drugs. We will compare
different mutant antibodies as ADCs in functional models, to identify optimal stability,
function and efficacy characteristics.

Publications

10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
BB/T008709/1 30/09/2020 29/09/2028
2395805 Studentship BB/T008709/1 30/09/2020 29/09/2024 Benjamin Esapa